NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

CompletedPhase 1

Sponsor: Sanofi

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Interventions: Humanized anti-Factor Bb monoclonal antibody, Placebo

Countries: United States

Primary objective * The tolerability and safety of SAR443809 Secondary * The PK parameters of SAR443809 * The PD activity of SAR443809 * The immunogenicity of SAR443809

Eligibility overview

Sex: ALL

Age: 18 Years to 45 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria: Having given written informed consent prior to undertaking any study-related procedure Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:

Any participant who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (2)

Glendale, California, United States
Baltimore, Maryland, United States